This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2017 May 1;28(5):914-916.

doi: 10.1093/annonc/mdx104.

PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?

P J Vlachostergios¹, A M Molina¹

Affiliations

PMID: 28379379
DOI: 10.1093/annonc/mdx104

Free article

Editorial

PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?

P J Vlachostergios et al. Ann Oncol. 2017.

Free article

. 2017 May 1;28(5):914-916.

doi: 10.1093/annonc/mdx104.

Authors

P J Vlachostergios¹, A M Molina¹

Affiliation

¹ Division of Hematology and Medical Oncology, Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, USA.

PMID: 28379379
DOI: 10.1093/annonc/mdx104

No abstract available

PubMed Disclaimer

Comment on

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.
Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN Jr, Tannir NM. Jonasch E, et al. Ann Oncol. 2017 Apr 1;28(4):804-808. doi: 10.1093/annonc/mdw676. Ann Oncol. 2017. PMID: 28049139 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- scite Smart Citations